Clinical trials: Tacrolimus
Atopic Dermatitis
Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients
To evaluate the clinical efficacy of the extended release formulation of tacrolimus (Advagraf®) in patients with severe atopic dermatitis, who can not be treated adequately with cyclosporine A because of side effects and/or…
- Trial name
- NCT01789619
- Testing
- Extended release tacrolimus (Advagraf®)
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- UMC Utrecht
Minimal Change Disease
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
To evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of MCD to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in…
- Trial name
- NCT06405100
- Testing
- Supportive care+Prednisone, Supportive care+Tacrolimus+Ripertamab, Supportive care+Ripertamab
- Volunteers
- 81 people
- Sponsor
- Air Force Military Medical University, China
Kidney Diseases
Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids
Kidney transplant patients will be treated with Thymoglobulin (5 days), tacrolimus (Prograf), and mycophenolate mofetil (Cellcept) from the time of transplant.
- Trial name
- NCT00170053
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Mayo Clinic
Acute Graft Rejection, Diabetes
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation…
- Trial name
- Astellas (NCT01265537)
- Testing
- Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Kidney Transplant Recipients, Old Age
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus…
- Trial name
- Neuro-KTR (NCT06751992)
- Testing
- Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Massachusetts General Hospital
Kidney Transplantation
A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.
This 2 arm study will compare the efficacy and safety of CellCept, combined with low or standard dose tacrolimus plus corticosteroids, in patients with kidney transplants.
- Trial name
- NCT00758602
- Testing
- mycophenolate mofetil, tacrolimus, standard dose, tacrolimus, low dose
- Where
- 6 sites in China
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Healthy
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).
- Trial name
- NCT05202145
- Testing
- ALXN2050, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Graft vs Host Disease
Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease
This study aims to compare efficacy and safety of tacrolimus/methotrexate with cyclosporine/methotrexate for graft versus host disease prophylaxis in paediatric allogeneic hematopoietic stem cell transplantation patients.
- Trial name
- NCT01788501
- Testing
- Tacrolimus, Cyclosporine, Methotrexate
- Where
- 3 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Liver Transplantation
A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients
To evaluate and to compare efficacy and safety of MR4 versus Prograf in patients undergoing primary liver transplantation.
- Trial name
- NCT00719745
- Testing
- Prograf, MR4
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Astellas Pharma Inc
Ocular Graft-versus-host Disease
Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT
Chronic GVHD (cGVHD) is a predominant cause of mortality and disability not related to relapse; it occurs in 30 to 70% of patients.
- Trial name
- NCT06348602
- Testing
- Cyclosporine ophthalmic solution 0.1%, Tacrolimus ophthalmic ointment 0.03%
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Pediatric Liver Transplantation
Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation
Our first aim is thus to investigate, retrospectively first and then prospectively, in de novo pediatric (living donor) liver recipients, the tacrolimus in vivo and in vitro metabolism and its variability with focus on…
- Trial name
- NCT02064777
- Testing
- Tacrolimus
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Kidney Transplantation
Genetic Factors on Outcomes of Kidney Transplant Patients With Tacrolimus-based Therapy
The purpose of this study is to identify the influence of genetic and clinical factors on the clinical outcomes of kidney transplant patients with tacrolimus (TAC) based immunosuppression in Taiwan.
- Trial name
- NCT03764670
- Where
- Taiwan
- Volunteers
- 98 people
- Sponsor
- National Taiwan University Hospital
Liver Transplantation
A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients
A study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable pediatric liver transplant patients converted from a Prograf® based immunosuppression regimen to a modified release tacrolimus based…
- Trial name
- NCT00282256
- Testing
- tacrolimus modified release (MR), tacrolimus
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Astellas Pharma Inc
Dermatitis, Atopic
Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment
A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and…
- Trial name
- NCT00480896
- Testing
- tacrolimus ointment
- Where
- 22 sites in Belgium, Czechia and 9 more
- Volunteers
- 250 people
- Sponsor
- Astellas Pharma Inc
Hematologic Neoplasms
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
This is a pilot study to evaluate the feasibility, safety and potential benefits of removing one immune suppressive drug called mycophenolate mofetil (MMF) from the standard allogenic stem cell transplant treatment protocol.
- Trial name
- OmitMMF (NCT05256537)
- Testing
- Omission of the drug mycophenolate mofetil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ronald Paquette
Transplant Recipient (Kidney)
Immune Monitoring-Guided Individualized Tacrolimus Therapy in Renal Transplant Recipients: An Observational Study and PK/PD Modeling
This study aims to resolve the clinical limitation that therapeutic drug monitoring (TDM) alone cannot accurately reflect the net immune status after kidney transplantation.
- Trial name
- NCT07815938
- Testing
- No interventional treatment, only observational data collection without clinical drug adjustment
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Liver Transplant
EVR and EPO for Liver Transplant Tolerance
This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five…
- Trial name
- EVEREST (NCT06832189)
- Testing
- Everolimus, Epoetin alfa
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplantation, Kidney Transplantation
Impact of P-gp, MRP2, ENT-1 and CNT3 on the Blood Concentration / Intra-PBMC Concentration of Tacrolimus
Prospective and monocentric pharmacokinetic study
- Trial name
- TRANS-TAC (NCT03910868)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Rennes University Hospital
Breast Cancer Lymphedema
Tacrolimus as Treatment of Breast Cancer-Related Lymphedema
BACKGROUND Breast cancer-related lymphedema is a severe and life-long side-effect to breast cancer treatment. The condition increases the risk of infections and decreases health-related quality of life (HR-QOL) in patients.
- Trial name
- NCT04541290
- Testing
- Protopic 0.1 % Topical Ointment
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
Graft-versus-host Disease
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
This is a single arm, open label, optimal 2-stage Simon design phase Ib-II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible…
- Trial name
- NCT04503616
- Testing
- Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- NYU Langone Health